| Identity and chemical specification | D-Chiro-inositol; CAS No. 643-12-9; molecular formula C6H12O6; relative molecular mass approximately 180.16 g/mol. | Certificate of analysis supported by HPLC or another validated identity and purity method; infrared spectrum may be requested for confirmation. | Customer-approved specification and a validated analytical procedure; pharmacopoeial requirements should be applied when specifically listed in the destination market. | Confirms that the supplied material is the declared stereoisomer and not a different inositol form or an unsuitable mixture. | Critical |
| Assay and purity | A common buyer specification is not less than 98.0% by HPLC, although the final limit should be agreed in the purchase specification. | Batch-specific HPLC chromatogram, method validation summary, system suitability data, and assay result. | ICH Q2 principles for analytical procedure validation; buyer-approved quality specification. | Controls potency, formulation consistency, and the commercial suitability of the ingredient. | Critical |
| Correct stereochemical form | The specification should clearly distinguish D-chiro-inositol from myo-inositol and other stereoisomers. | Validated chromatographic separation, reference standard traceability, and supporting structural or spectroscopic data where appropriate. | ICH Q6A concepts for specifications and ICH Q2 principles for method validation. | Stereoisomer identity directly affects product labeling, dosage calculations, and intended use. | Critical |
| Residual solvents | Solvents should comply with the applicable limits for the intended market and manufacturing process. | Gas chromatography test report identifying detected solvents and reporting results in ppm or mg/kg. | ICH Q3C, Residual Solvents; destination-country requirements may impose additional controls. | Protects consumers from process-related solvent exposure and supports regulatory review. | Critical |
| Heavy metals and elemental impurities | Lead, arsenic, cadmium, and mercury should be controlled according to the finished-product risk assessment and local limits. | ICP-MS or ICP-OES report from a qualified laboratory, including reporting limits and sample preparation details. | ICH Q3D, Elemental Impurities; applicable food or supplement regulations in the importing country. | Helps manage contamination risks from raw materials, equipment, water, and processing aids. | Critical |
| Microbiological quality | Total aerobic microbial count, total yeast and mold count, and specified pathogens should meet the buyer's finished-use specification. | Batch microbiology report covering at least the agreed microbial limits and absence or limits for relevant pathogens. | USP <61>, USP <62>, or equivalent validated methods; local food and dietary supplement requirements. | Reduces contamination risk during storage, handling, and incorporation into finished products. | Critical |
| Manufacturing quality system | Documented quality management system with controlled procedures, deviation handling, CAPA, change control, and batch traceability. | Current quality certificates, audit report or audit questionnaire, SOP index, and sample batch records subject to confidentiality controls. | ISO 9001 for quality management; GMP principles appropriate to the product category and destination market. | Shows whether quality is controlled systematically rather than relying only on final-product testing. | Critical |
| Raw-material traceability | Each batch should be traceable from incoming raw materials through processing, packaging, testing, release, and shipment. | Lot-number system, supplier qualification records, traceability exercise, and documented recall procedure. | GMP traceability principles; ISO 22000 or HACCP controls where applicable to food-chain operations. | Supports investigations, targeted recalls, and verification of consistent sourcing. | High |
| Stability and shelf life | Shelf life should be supported by stability data under the proposed packaging and storage conditions. | Real-time or accelerated stability results for assay, appearance, moisture, impurities, and microbiological quality. | ICH Q1A principles may be used as a technical reference; the final protocol should reflect the product and market. | Confirms that purity and physical quality remain acceptable until the stated expiry date. | High |
| Moisture and physical properties | Moisture, appearance, particle size, bulk density, and solubility should match the agreed formulation requirements. | Loss-on-drying or Karl Fischer result, particle-size distribution, visual inspection, and product-specific physical test data. | Buyer-approved specification and validated in-house or compendial methods where available. | Influences flowability, blending uniformity, dissolution, packaging performance, and production yield. | High |
| Contaminant and allergen control | Risk assessment should address pesticides, mycotoxins, allergens, GMO status, and other contaminants relevant to the source and process. | Risk assessment, supplier declarations, targeted laboratory tests, allergen statement, and GMO statement where required. | Importing-country food and supplement legislation; Codex and customer-specific requirements may apply. | Supports compliant labeling and reduces the risk of rejected shipments or product recalls. | High |
| Packaging and storage | Food-contact or suitable pharmaceutical-grade packaging should protect the powder from moisture, light, and contamination. | Packaging specification, inner-liner description, seal-integrity controls, storage instructions, and transport qualification where relevant. | Applicable packaging, food-contact, and good distribution practice requirements in the destination market. | Prevents moisture uptake, contamination, damage, and loss of quality during international transport. | High |
| Documentation and export readiness | Complete commercial and quality documentation should be available before shipment. | Commercial invoice, packing list, certificate of analysis, specification sheet, safety data sheet, certificate of origin, and export documents as applicable. | Destination-country customs, labeling, food, dietary supplement, or pharmaceutical-import rules. | Reduces customs delays and enables the buyer to complete technical and regulatory review. | High |
| Change notification and complaint handling | Written procedures should cover process changes, site changes, specification changes, complaints, investigations, and recalls. | Quality agreement, change-notification procedure, complaint-response target, CAPA records, and recall contact details. | GMP quality-system principles and contractual quality-agreement requirements. | Provides control over post-approval changes and ensures timely response to quality issues. | High |
| Independent verification | Pre-shipment or periodic third-party testing should be considered for new suppliers, high-risk batches, or regulatory-sensitive applications. | Independent laboratory report with sample chain of custody, test methods, results, and laboratory accreditation details. | ISO/IEC 17025 for testing-laboratory competence. | Provides an impartial check of supplier results and strengthens qualification decisions. | Medium to High |
| Supply continuity and commercial capability | Evaluate validated production capacity, lead time, minimum order quantity, contingency planning, and consistent batch availability. | Capacity statement, production lead-time history, inventory policy, business-continuity plan, and sample-to-commercial-batch comparison. | Customer supply agreement and approved supplier qualification procedure. | Reduces the risk of shortages, inconsistent quality, and unexpected delivery interruptions. | Medium |